SCHEMBL14969155

SCHEMBL14969155

CCOC(=O)c1nn(C(C)C)c(=O)n(-c2ccc(F)cc2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
LMNA P02545 1/20 0.51
RAB9A P51151 1/20 0.51
POLB P06746 1/20 0.51
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.47
APP P05067 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SLC5A1 P13866 1/20 0.47
SLC5A2 P31639 1/20 0.47
MET P08581 9/20 0.46
AXL P30530 6/20 0.46
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45
ALDH1A1 P00352 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TYRO3 Q06418 3/20 0.43
MERTK Q12866 3/20 0.43
ELANE P08246 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21778084 0.89 LMNA (0.49) NPC1LMNARAB9APOLBMEN1
SCHEMBL19377733 0.88 ALDH1A1 (0.50) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL14970191 0.85 NPC1 (0.55) NPC1LMNARAB9APOLBMEN1
SCHEMBL14969120 0.83 MET (0.48) LMNAPOLBKMT2AL3MBTL1MET
SCHEMBL29814284 0.82 MET (0.47) POLBMEN1KMT2AL3MBTL1MET
SCHEMBL18186597 0.80 POLB (0.44) LMNAPOLBMETAXLTYRO3
SCHEMBL14969166 0.79 POLB (0.54) NPC1LMNARAB9APOLBMEN1
SCHEMBL21785519 0.77 MET (0.40) NPC1POLBKMT2AL3MBTL1MET
SCHEMBL14969063 0.75 AXL (0.47) NPC1LMNARAB9APOLBMET
SCHEMBL14968994 0.75 NPC1 (0.51) NPC1LMNARAB9APOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116283916-B Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof 中国科学院上海药物研究所 2024-06-11 CN disclosed
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2024-05-30 US disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 EP disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 US disclosed
CN-116283916-A Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof 中国科学院上海药物研究所 2023-06-23 CN disclosed
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2023-01-12 US disclosed
CN-112457295-B Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof 中国科学院上海药物研究所 2022-07-26 CN disclosed
EP-4029862-A1 COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2022-07-20 EP disclosed
EP-3843850-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES Array BioPharma Inc. (US) 2021-07-07 EP disclosed
CN-112930215-A Pyrazolo [3, 4-b ] pyridine compounds as TAM and MET kinase inhibitors 阿雷生物药品公司 2021-06-08 CN disclosed
EP-3087070-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE Ignyta, Inc. (US) 2016-11-02 EP disclosed
EP-3045453-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS CEPHALON, INC. (US) 2016-07-20 EP disclosed
US-9120778-B2 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. (US) 2015-09-01 US disclosed
US-20150209358-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS CEPHALON, INC. 2015-07-30 US disclosed
US-20150210670-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS CEPHALON, INC. 2015-07-30 US disclosed
WO-2015100117-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE CEPHALON, INC. (US) 2015-07-02 WO disclosed
US-9029538-B2 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. (US) 2015-05-12 US disclosed
EP-2780338-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS Cephalon, Inc. (US) 2014-09-24 EP disclosed
US-20140275077-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS CEPHALON, INC. (US) 2014-09-18 US disclosed
WO-2013074633-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS CEPHALON, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET NPC1 4245/4885LMNA 3554/4885RAB9A 699/4885
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET NPC1 4222/4885LMNA 3447/4885RAB9A 755/4885
US-20150210670-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS AXL, RET, BRAF NPC1 4773/4885LMNA 3405/4885RAB9A 909/4885
US-20140275077-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS AXL, RET, BRAF NPC1 4773/4885LMNA 3405/4885RAB9A 909/4885
US-20150209358-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS AXL, RET, BRAF NPC1 4773/4885LMNA 3405/4885RAB9A 909/4885
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases RET, MERTK, MET NPC1 4245/4885LMNA 3554/4885RAB9A 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.